Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients With Advanced Solid Tumor Malignancies

Next Previous
X
Search
Trial Profile

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients With Advanced Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RSC-1255 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors RasCal Therapeutics

    • Most Recent Events

    • 01 Jul 2024 Time frame changed from Approximately 12 months to Approximately 30 months for Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy outcome measure.
    • 01 Jul 2024 Planned End Date changed from 5 Mar 2024 to 1 Sep 2025.
    • 01 Jul 2024 Planned primary completion date changed from 16 Jan 2024 to 2 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top